港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

武汉艾米森生命科技股份有限公司（临时代码）

成交量：- -

成交额：- -

市值：- -

市盈率：- -

高：- -

开：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：- -

香港流通股本：- -

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

市销率: - -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

新股消息 | 艾米森拟港股上市中国证监会要求补充说明股权变动等事项

艾米森冲港股年营收不足千万元关联交易撑起半边天

艾米森冲刺港股半数收入涉关联交易

癌症早筛公司艾米森IPO：营收额不足千万靠缩减费用减亏关联方或股东贡献超6成营收

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/91270"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"91270","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91270\",,,,,undefined,":{"symbol":"91270","market":"HK","secType":"STK","nameCN":"武汉艾米森生命科技股份有限公司（临时代码）","latestPrice":0,"timestamp":1764921600000,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":0,"latestTime":"12-05 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":0,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1764898200000,1764907200000],[1764910800000,1764921600000]],"volumeRatio":0,"lotSize":0,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91270\",,,,,undefined,":{"symbol":"91270","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91270\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91270\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91270\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91270\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583950807","title":"新股消息 | 艾米森拟港股上市 中国证监会要求补充说明股权变动等事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2583950807","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583950807?lang=zh_cn&edition=fundamental","pubTime":"2025-11-14 19:57","pubTimestamp":1763121472,"startTime":"0","endTime":"0","summary":"中国证监会国际司公示10家企业补充材料要求，其中，公示提到要求艾米森补充说明股权变动、股东情况、业务经营等事项。据港交所9月28日披露，武汉艾米森生命科技股份有限公司向港交所主板提交上市申请书，联席保荐人为建银国际、交银国际。招股书显示，艾米森是一家领先的早期癌症检测公司，战略聚焦于高发病率、高死亡率的癌症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369543.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91270"],"gpt_icon":0},{"id":"2579634451","title":"艾米森冲港股年营收不足千万元 关联交易撑起半边天","url":"https://stock-news.laohu8.com/highlight/detail?id=2579634451","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579634451?lang=zh_cn&edition=fundamental","pubTime":"2025-10-30 11:08","pubTimestamp":1761793690,"startTime":"0","endTime":"0","summary":"中国经济网北京10月30日讯 近日，武汉艾米森生命科技股份有限公司 向港交所递交上市申请，联席保荐人为建银国际与交银国际。　　新浪证券近日刊载《癌症早筛公司艾米森IPO：营收额不足千万靠缩减费用减亏 关联方或股东贡献超6成营收》。文章指出，2023年、2024年及2025年上半年，艾米森的收入分别为623.3万元、723.8万元和651.3万元。尽管2025年上半年同比增长103%，但整体营收规模仍不足千万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251030/31750212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["91270"],"gpt_icon":0},{"id":"2579491990","title":"艾米森冲刺港股 半数收入涉关联交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2579491990","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579491990?lang=zh_cn&edition=fundamental","pubTime":"2025-10-29 04:35","pubTimestamp":1761683700,"startTime":"0","endTime":"0","summary":"　　近日，武汉艾米森生命科技股份有限公司向港交所递交上市申请，联席保荐人为建银国际与交银国际。　　作为一家成立于2015年的公司，艾米森聚焦近年来兴起的癌症早筛技术，自称旗下核心产品艾光乐仅需用1毫升尿液样本即可实现尿路上皮癌的非侵入性检测。但前沿技术的背后，公司至今仍未盈利，还存在研发投入存疑和大额关联交易的情况。　　回顾艾米森近年来的业绩表现，大额的关联交易无疑是不容忽视的一环。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-10-29/doc-infvnxkx8370951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91270"],"gpt_icon":0},{"id":"2577552077","title":"癌症早筛公司艾米森IPO：营收额不足千万靠缩减费用减亏 关联方或股东贡献超6成营收","url":"https://stock-news.laohu8.com/highlight/detail?id=2577552077","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577552077?lang=zh_cn&edition=fundamental","pubTime":"2025-10-24 10:38","pubTimestamp":1761273480,"startTime":"0","endTime":"0","summary":"　　近日，武汉艾米森生命科技股份有限公司正式向港交所递交招股书，联席保荐人为建银国际与交银国际。艾米森成立于2015年、专注于癌症早期筛查的体外诊断公司，愿景是成为全球肿瘤早筛的领先者。艾米森的上市尝试，恰逢行业标杆企业诺辉健康因财务造假停牌18个月、面临退市危机。被誉为中国癌症早筛第一股的企业坠落神坛，让整个行业笼罩在阴影之中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-10-24/doc-infuyerp1519536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91270"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/91270\",params:#limit:6,delay:false,,,undefined,":[]}}